Neurol. praxi. 2019;20(5):332-336 | DOI: 10.36290/neu.2019.047

Genetics of hereditary spastic paraplegias

RNDr. Anna Uhrová Mészárosová, Ph.D.1, prof. MUDr. Pavel Seeman, Ph.D.1,2
1 DNA laboratoř Kliniky dětské neurologie, 2. LF UK a FN Motol, Praha
2 Centrum lékařské genetiky a fetální medicíny, GENNET, s. r. o., Praha

Hereditary spastic parapalegia (HSP or SPG) is clinically and genetically heterogenous serious disease of the central motoneuron. It is characterised by progressive spasticity and weakness of lower libms leading to progressive gait impairement. Pathogenic variants causing HSP in more than 90 genes or gene loci where described to date. Methods of new generation sequencing allow us to map the genetic background of HSP and to bring new knowledges about clinical spectrum of particular types of HSP. There exist at least 12 types of HSP among Czech HSP patients, the most frequent types are SPG4, SPG31 with autosomal dominant and SPG7 and SPG11 with autosomal recessive mode of inheritance, similarly like in other European countries. In spite of previously published data from other populations the occurence of SPG3 is suprisingly low in the Czech Republic. The percentage of genetically and by DNA testing evaluated patients is much higher among familial patients (more affected persons in the family) compared to the sporadic ones. These facts should be taken into account for genetic testing consideration.

Keywords: HSP, SPG4, SPG31, SPG7, SPG11, sporadic and familial patients

Received: June 4, 2019; Accepted: June 18, 2019; Prepublished online: June 18, 2019; Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Uhrová Mészárosová A, Seeman P. Genetics of hereditary spastic paraplegias. Neurol. praxi. 2019;20(5):332-336. doi: 10.36290/neu.2019.047.
Download citation

References

  1. Coutinho PL, Ruano JL, Loureiro VT, Cruz J, Barros A, Tuna C, Barbot J, Guimaraes I, Alonso I, Silveira J, Sequeiros J. Marques Neves, Serrano P, Silva MC. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study, JAMA Neurol, 2013; 70: 746-755. Go to original source... Go to PubMed...
  2. de Bot ST, van den Elzen RT, Mensenkamp AR, Schelhaas HJ, Willemsen MA, Knoers NV, Kremer HP, van de Warrenburg BP, Scheffer H. Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations. J Neurol Neurosurg Psychiatry 2010; 81: 1073-1078. Go to original source... Go to PubMed...
  3. Depienne CC, Tallaksen JY, Lephay B, Bricka S, Poea-Guyon B, Fontaine P, Labauge A, Brice A. Durr. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet 2006; 43: 259-265. Go to original source... Go to PubMed...
  4. Elert-Dobkowska E, Stepniak I, Krysa W, Rajkiewicz M, Rakowicz M, Sobanska A, Rudzinska M, Wasielewska A, Pilch J, Kubalska J, Lipczynska-Lojkowska W, Kulczycki J, Kurdziel K, Sikorska A, Beetz C, Zaremba J, Sulek A. Molecular spectrum of the SPAST, ATL1 and REEP1 gene mutations associated with the most common hereditary spastic paraplegias in a group of Polish patients. J Neurol Sci 2015; 359: 35-39. Go to original source... Go to PubMed...
  5. Erichsen AK, Inderhaug E, Mattingsdal M, Eiklid K, Tallaksen CM. Seven novel mutations and four exon deletions in a collection of Norwegian patients with SPG4 hereditary spastic paraplegia, Eur J Neurol, 2007; 14: 809-814. Go to original source... Go to PubMed...
  6. Fink JK. Advances in the hereditary spastic paraplegias, Exp Neurol, 2003; 184(Suppl. 1): S106-10. Go to original source... Go to PubMed...
  7. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol 2013; 126: 307-328. Go to original source... Go to PubMed...
  8. Fonknechten N, Mavel D, Byrne P, Davoine CS, Cruaud C, Bonsch D, Samson D, Coutinho P, Hutchinson M, McMonagle P, Burgunder JM, Tartaglione A, Heinzlef O, Feki I, Deufel T, Parfrey N, Brice A, Fontaine B, Prud'homme JF, Weissenbach J, Durr A, Hazan J. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet 2000; 9: 637-644. Go to original source... Go to PubMed...
  9. Hadjivassiliou M, Martindale J, Shanmugarajah P, Grunewald RA, Sarrigiannis PG, Beauchamp N, Garrard K, Warburton R, Sanders DS, Friend D, Duty S, Taylor J, Hoggard N. Causes of progressive cerebellar ataxia: prospective evaluation of 1 500 patients. J Neurol Neurosurg Psychiatry 2017; 88: 301-309. Go to original source... Go to PubMed...
  10. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet 1983; 1: 1151-1155. Go to original source... Go to PubMed...
  11. Chrestian N, Dupre N, Gan-Or Z, Szuto A, Chen S, Venkitachalam A, Brisson JD, Warman-Chardon J, Ahmed S, Ashtiani S, MacDonald H, Mohsin N, Mourabit-Amari K, Provencher P, Boycott KM, Stavropoulos DJ, Dion PA, Ray PN, Suchowersky O, Rouleau GA, Yoon G. Clinical and genetic study of hereditary spastic paraplegia in Canada. Neurol Genet 2017; 3: e122. Go to original source... Go to PubMed...
  12. Ishiura H, Takahashi Y, Hayashi T, Saito K, Furuya H, Watanabe M, Murata M, Suzuki M, Sugiura A, Sawai S, Shibuya K, Ueda N, Ichikawa Y, Kanazawa I, Goto J, Tsuji S. Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses. J Hum Genet 2014; 59: 163-172. Go to original source... Go to PubMed...
  13. Kim TH, Lee JH, Park YE, Shin JH, Nam TS, Kim HS, Jang HJ, Semenov A, Kim SJ, Kim DS. Mutation analysis of SPAST, ATL1, and REEP1 in Korean Patients with Hereditary Spastic Paraplegia. J Clin Neurol 2014; 10: 257-261. Go to original source... Go to PubMed...
  14. Kumar KR, Blair NF, Vandebona H, Liang C, Ng K, Sharpe DM, Grunewald A, Golnitz U, Saviouk V, Rolfs A, Klein C, Sue CM. Targeted next generation sequencing in SPAST-negative hereditary spastic paraplegia. J Neurol 2013; 260: 2516-2522. Go to original source... Go to PubMed...
  15. Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol 2014; 261: 518-539. Go to original source... Go to PubMed...
  16. Lu X, Cen Z, Xie F, Ouyang Z, Zhang B, Zhao G, Luo W. Genetic analysis of SPG4 and SPG3A genes in a cohort of Chinese patients with hereditary spastic paraplegia. J Neurol Sci 2014; 347: 368-371. Go to original source... Go to PubMed...
  17. Lynch DS, Koutsis G, Tucci A, Panas M, Baklou M, Breza M, Karadima G, Houlden H. Hereditary spastic paraplegia in Greece: characterisation of a previously unexplored population using next-generation sequencing. Eur J Hum Genet 2016; 24: 857-863. Go to original source... Go to PubMed...
  18. Meszarosova AU, Grecmalova D, Brazdilova M, Dvorackova N, Kalina Z, Cermakova M, Vavrova D, Smetanova I, Stanek D, Seeman P. Disease-Causing Variants in the ATL1 Gene Are a Rare Cause of Hereditary Spastic Paraplegia among Czech Patients. Ann Hum Genet 2017; 81: 249-257. Go to original source... Go to PubMed...
  19. Meszarosova AU, Putzova M, Cermakova M, Vavrova D, Dolezalova K, Smetanova I, Stejskal D, Beetz C, Seeman P. SPAST mutation spectrum and familial occurrence among Czech patients with pure hereditary spastic paraplegia. J Hum Genet 2016; 61: 845-850. Go to original source... Go to PubMed...
  20. Namekawa M, Ribai P, Nelson I, Forlani S, Fellmann F, Goizet C, Depienne C, Stevanin G, Ruberg M, Durr A, Brice A. SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years. Neurology 2006; 66: 112-114. Go to original source... Go to PubMed...
  21. Park H, Kang SH, Park S, Kim SY, Seo SH, Lee SJ, Lee JA, Cho SI, Sung JJ, Lee KW, Kim JY, Park SS, Seong MW. Mutational spectrum of the SPAST and ATL1 genes in Korean patients with hereditary spastic paraplegia. J Neurol Sci 2015; 357: 167-172. Go to original source... Go to PubMed...
  22. Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 2014; 42: 174-183. Go to original source... Go to PubMed...
  23. Sauter S, Miterski B, Klimpe S, Bonsch D, Schols L, Visbeck A, Papke T, Hopf HV, Engel W, Deufel T, Epplen JT, Neesen J. Mutation analysis of the spastin gene (SPG4) in patients in Germany with autosomal dominant hereditary spastic paraplegia. Hum Mutat 2002; 20: 127-132. Go to original source... Go to PubMed...
  24. Schule R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, Klimpe S, Gallenmuller C, Kurzwelly D, Henkel D, Rimmele F, Stolze H, Kohl Z, Kassubek J, Klockgether T, Vielhaber S, Kamm C, Klopstock T, Bauer P, Zuchner S, Liepelt-Scarfone I, Schols L. Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol 2016; 79: 646-658. Go to original source... Go to PubMed...
  25. Verny C, Guegen N, Desquiret V, Chevrollier A, Prundean A, Dubas F, Cassereau J, Ferre M, Amati-Bonneau P, Bonneau D, Reynier P, Procaccio V. Hereditary spastic paraplegia-like disorder due to a mitochondrial ATP6 gene point mutation. Mitochondrion 2011; 11: 70-75. Go to original source... Go to PubMed...
  26. Zuchner S, Wang G, Tran-Viet KN, Nance MA, Gaskell PC, Vance JM, Ashley-Koch AE, Pericak-Vance MA. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am J Hum Genet 2006; 79: 365-369. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.